drugset / Trial / NCT00603772

Clinical Evaluation of the Photoallergy Potential of Atralin Gel

NCT00603772

Phase 1 Completed 40 enrolled Coria Laboratories, Ltd.
RandomizedSingle-groupSingle-blind

Summary

To assess the potential of tretinoin gel 0.05% and its vehicle to produce photoallergic reactions, measured as skin reactions following induction and challenge.

Timeline

Start
2008-01
Primary completion
2008-03
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Tretinoin Small molecule 0.05 %

Indications

No indication recorded.